The paediatric population which needs treatment is small compared to the adult population, hence the necessity for global drug development. Paediatric legislation is not global, so collaboration to achieve agency alignment is the only route to global drug development. Harris Dalrymple, Mark Sorrentino, and Dr. Martine Dehlinger-Kremer at PRA Health Sciences explore the similarities and differences in paediatric legislations in the US and the EU.